Prodotto aggiunto correttamente al carrello.

discount label
H-ELAGIGILTV^-OH
Visualizzare in 3D

Biosynth logo

H-ELAGIGILTV^-OH

Rif. 3D-PP47742

Dimensione non definitaPrezzo su richiesta
Consegna stimata in Stati Uniti, il Martedì 10 Dicembre 2024

Informazioni sul prodotto

Nome:
H-ELAGIGILTV^-OH
Descrizione:

Peptide H-ELAGIGILTV^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-ELAGIGILTV^-OH include the following: Rational design of peptide-based tumor vaccines WS Meng , LH Butterfield - Pharmaceutical research, 2002 - Springerhttps://link.springer.com/article/10.1023/A:1016497818471 Peptide super-agonist enhances T-cell responses to melanoma SAE Galloway, G Dolton , M Attaf, A Wall - Frontiers in , 2019 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2019.00319/full Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres S Walter, L Herrgen, O Schoor, G Jung - The Journal of , 2003 - journals.aai.orghttps://journals.aai.org/jimmunol/article/171/10/4974/1858 Altered peptide ligands revisited: Vaccine design through chemically modified HLA-A2-restricted T cell epitopes R Hoppes, R Oostvogels , JJ Luimstra - The Journal of , 2014 - journals.aai.orghttps://journals.aai.org/jimmunol/article/193/10/4803/97379 Modification of MHC Anchor PTATCR Binding, RG Heteroclitic - J. Immunol, 2010 - Citeseerhttps://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=cf719cdb0be3af6be38c9b96c3dfdbb892f3435c From peptides to small molecules: an intriguing but intricated way to new drugs PL Scognamiglio, C Di Natale - Current medicinal , 2013 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmc/2013/00000020/00000031/art00001 Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes P Sliz , O Michielin, JC Cerottini, I Luescher - The Journal of , 2001 - journals.aai.orghttps://journals.aai.org/jimmunol/article/167/6/3276/33980 Convergence of the specificity and cross-reactivity of multiple T cell receptors isolated against a single cancer peptide/HLA complex P Sharma , DT Harris, MV Hager, DM Kranz - Cancer Research, 2018 - AACRhttps://aacrjournals.org/cancerres/article-abstract/78/13_Supplement/3581/627815 Fluorescence labeling of anchor-modified Mart-1 peptide for increasing its affinity for HLA-A* 0201: Hit two targets with one arrow P Fattahi, N Salehi , Z Azizi - Journal of Peptide , 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.3480 CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity P Baumgaertner, J Schmidt, CM Costa-Nunes - Frontiers in , 2022 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2022.973986/full Synthesis of Glycocluster-Tumor Antigenic Peptide Conjugates for Dendritic Cell Targeting O Srinivas, P Larrieu, E Duverger - Bioconjugate , 2007 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/bc070026g Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1. 24 O Christensen, A Lupu, S Schmidt - Journal of , 2009 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2009/07000/Recognition_of_Shared_Melanoma_Antigens_in.8.aspx Immunogenic decapeptide in melanoma immunotherapy NK Mishra, AK Sharma , TK Mukherjee - Journal of molecular modeling, 2016 - Springerhttps://link.springer.com/article/10.1007/s00894-016-3140-8 MHC Class I Molecules with NA CTLs, SCD Binding - J. Immunol, 2010 - Citeseerhttps://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=f8202eb4619e178604accb92076d32557c5daa64 Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study N Meidenbauer, S Vogl, M Laumer, J Heymann - Cancer Cell , 2004 - Springerhttps://link.springer.com/article/10.1186/1475-2867-4-S1-S10 Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue MJ Maeurer , A Necker, RD Salter - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.1580 Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-126(27L)-35 M Tarbe, JJ Miles , ESJ Edwards , KM Miles - , 2020 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202000038 Soluble HLA-I/peptide monomers mediate antigen-specific CD8 T cell activation through passive peptide exchange with cell-bound HLA-I molecules M Allard , R Oger, H Benlalam, L Florenceau - The Journal of , 2014 - journals.aai.orghttps://journals.aai.org/jimmunol/article/192/11/5090/92443 Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry JJ Miles , MP Tan, G Dolton - The Journal of , 2018 - Am Soc Clin Investighttps://www.jci.org/articles/view/91512 Detection of antigen-specific T-cells with MHC/peptide-tetramer-complexes G Tully, E Jager, MJ Maeurer - Clinical and Applied Immunology Reviews, 2002 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1529104902000569 MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A* 0201-restricted, Melan-A-derived peptide after active intracellular processing G Held, A Wadle, N Dauth - European journal of , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.200636545 Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complex F Yuan, T Georgiou, T Hillon, E Gostick - Section F: Structural , 2007 - scripts.iucr.orghttps://scripts.iucr.org/cgi-bin/paper?pu5196 TCR-induced alteration of primary MHC peptide anchor residue F Madura, PJ Rizkallah , M Legut - European journal of , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.201948085 Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type E Jäger, R Salter, C Castelli, H Höhn - The Journal of , 2002 - journals.aai.orghttps://journals.aai.org/jimmunol/article/168/6/2766/34711 Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8 T cells using HLA-A2 E Jager, R Salter, C Castelli, H Höhn, K Freitag - J. Immunol, 2002 - academia.eduhttps://www.academia.edu/download/47681918/Impact_of_antigen_presentation_on_TCR_mo20160731-32057-yvft53.pdf Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1 E Jager, H Höhn, A Necker, R Förster - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.10165 Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition DK Cole , ESJ Edwards , KK Wynn - The Journal of , 2010 - journals.aai.orghttps://journals.aai.org/jimmunol/article/185/4/2600/103229 Diversity of the fine specificity displayed by HLA-A* 0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide D Valmori, N Gervois, D Rimoldi - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/161/12/6956/1064 Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues D Valmori, JF Fonteneau , CM Lizana - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/160/4/1750/905 Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological C Douat-Casassus, N Marchand-Geneste - Molecular , 2006 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2006/mb/b518044a Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells C Douat-Casassus, N Marchand-Geneste - Journal of medicinal , 2007 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm0613368 Survival and Tumor Localization of A Mackensen , S Vogl, J Heymann, R Andreesen - J , 2003 - researchgate.nethttps://www.researchgate.net/profile/Joerg-Marienhagen/publication/10912107_Survival_and_Tumor_Localization_of_Adoptively_Transferred_Melan-A-Specific_T_Cells_in_Melanoma_Patients/links/568ba9a008ae051f9afc55e7/Survival-and-Tumor-Localization-of-Adoptively-Transferred-Melan-A-Specific-T-Cells-in-Melanoma-Patients.pdf Stability and CTL activity of N-terminal glutamic acid containing peptides A Beck , MC Bussat, C Klinguer-Hamour - Journal of Peptide , 2001 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-3011.2001.00895.x Peptides as tools and drugs for immunotherapies A Beck , C Klinguer-Hamour, MC Bussat - Journal of Peptide , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.852 Peptide-based strategies for targeted tumor treatment and imaging A Ayo, P Laakkonen - Pharmaceutics, 2021 - mdpi.comhttps://www.mdpi.com/1999-4923/13/4/481

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP47742 H-ELAGIGILTV^-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".